Literature DB >> 10692630

Ziconotide for the treatment of severe spasticity after spinal cord injury.

B Ridgeway1, M Wallace, A Gerayli.   

Abstract

Spasticity is a major clinical manifestation of spinal cord injury and upper motor neuron syndrome.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10692630     DOI： 10.1016/s0304-3959(99)00255-9

Source DB:  PubMed          Journal:  Pain        ISSN： 0304-3959            Impact factor:   6.961


  7 in total

Review 1.  Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.

Authors:  Terrance P Snutch
Journal:  NeuroRx       Date:  2005-10

2.  Spinal Cord Injury Provoked Neuropathic Pain and Spasticity, and Their GABAergic Connection.

Authors:  Ankita Bhagwani; Manjeet Chopra; Hemant Kumar
Journal:  Neurospine       Date:  2022-09-30

Review 3.  Molecular pharmacology of high voltage-activated calcium channels.

Authors:  Clinton J Doering; Gerald W Zamponi
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

Review 4.  Intrathecal analgesic drug therapy.

Authors:  Alan Farrow-Gillespie; Kimberly M Kaplan
Journal:  Curr Pain Headache Rep       Date:  2006-02

Review 5.  Discovery and Development of Calcium Channel Blockers.

Authors:  Théophile Godfraind
Journal:  Front Pharmacol       Date:  2017-05-29       Impact factor: 5.810

6.  Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog.

Authors:  Tony L Yaksh; Annelies de Kater; Robin Dean; Brookie M Best; George P Miljanich
Journal:  Neuromodulation       Date:  2012-07-02

7.  Botulinum Toxin Type A Possibly Affects Cav3.2 Calcium Channel Subunit in Rats with Spinal Cord Injury-Induced Muscle Spasticity.

Authors:  Kening Ma; Dan Zhu; Chunguo Zhang; Lijie Lv
Journal:  Drug Des Devel Ther       Date:  2020-07-28       Impact factor: 4.162
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.